So­ci­etal CD­MO lands NCI pack­ag­ing deal for an­ti-tu­mor cap­sules fol­low­ing re­brand

In the first deal since it re­brand­ed, So­ci­etal CD­MO has land­ed an agree­ment with the Na­tion­al Can­cer In­sti­tute’s Di­vi­sion of Can­cer Treat­ment and Di­ag­no­sis to man­u­fac­ture and pack­age am­mo­ni­um tetrathiomolyb­date cap­sules.

ATTM cap­sules are be­lieved to have the po­ten­tial to en­hance the ac­tiv­i­ty of plat­inum-based an­ti­tu­mor agents. The CD­MO will pro­vide scal­able man­u­fac­tur­ing for the pro­duc­tion of 100 mg cap­sules, and car­ry out a 36-month shelf life study. The project is par­tial­ly fund­ed with funds from the Na­tion­al In­sti­tutes of Health.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER